SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Gold/Mining/Energy : Inflazyme Pharmaceuticals (T.IZP)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Rob who wrote (1335)11/25/1999 1:44:00 PM
From: Sean Janzen  Read Replies (1) of 1501
 
I cannot say whether ICOS poses a serious threat to IZP's PDE work. Both companies look to be preparing to initiate Human Clinical Studies on numerous drugs from their respective PDE work.

I only hope that IZP can emulate ICOS' success. ICOS has gone from $4. to $48 over the last 5 years. They have not had a single drug complete phase III studies.

Bruce, the buy recommendation comes with an earning estimate or $0.19 for next year (March 2001).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News